Limbal Stem Cell Deficiency
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BioTherapeutics IncVA - Blacksburg
1 program1
CSB-001 Ophthalmic Solution 0.1%Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
RHEACELLLSC2
BioTherapeutics IncCSB-001 Ophthalmic Solution 0.1%
Clinical Trials (2)
Total enrollment: 91 patients across 2 trials
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD
Start: Jul 2019Est. completion: Sep 202316 patients
Phase 1/2Unknown
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
Start: May 2024Est. completion: Dec 202775 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 91 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.